Yen Ying Lim1, Pawel Kalinowski2, Robert H Pietrzak3, Simon M Laws4,5,6, Samantha C Burnham7, David Ames8,9, Victor L Villemagne1,10,11, Christopher J Fowler1, Stephanie R Rainey-Smith4, Ralph N Martins4, Christopher C Rowe10,11, Colin L Masters1, Paul T Maruff1,2. 1. The Florey Institute of Neuroscience and Mental Health, University of Melbourne, Parkville, Victoria, Australia. 2. CogState, Ltd, Melbourne, Victoria, Australia. 3. Department of Psychiatry, Yale University School of Medicine, New Haven, Connecticut. 4. Centre of Excellence for Alzheimer's Disease Research and Care, Edith Cowan University, Joondalup, Western Australia, Australia. 5. Sir James McCusker Alzheimer's Disease Research Unit, Hollywood Private Hospital, Perth, Western Australia, Australia. 6. Cooperative Research Centre for Mental Health, Carlton, Victoria, Australia. 7. Commonwealth Scientific and Industrial Research Organisation Preventative Health National Research Flagship, Australian e-Health Research Centre, Brisbane, Queensland, Australia. 8. Academic Unit for Psychiatry of Old Age, St Vincent's Health, University of Melbourne, Kew, Victoria, Australia. 9. National Ageing Research Institute, Parkville, Victoria, Australia. 10. Department of Nuclear Medicine and Centre for PET (Positron Emission Tomography), Austin Health, Heidelberg, Victoria, Australia. 11. Department of Medicine, Austin Health, University of Melbourne, Heidelberg, Victoria, Australia.
Abstract
Importance: Older age, high levels of β-amyloid (Aβ), and the presence of the apolipoprotein E (APOE) ε4 allele are risk factors for Alzheimer disease (AD). However, the extent to which increasing age, Aβ, and ε4 are associated with memory decline remains unclear, and the age at which memory decline begins for Aβ-positive ε4 carriers and noncarriers has not been determined. Objective: To determine the association of age, Aβ level, and APOE ε4 with memory decline in a large group of cognitively healthy older adults. Design, Setting, and Participants: This longitudinal observational study included cognitively healthy older adults (age >60 years) enrolled in the Australian Imaging, Biomarkers and Lifestyle (AIBL) study from March 31, 2006, through March 31, 2017; of 1583 individuals enrolled, 1136 refused or were excluded owing to other criteria (eg, having mild cognitive impairment or AD). Participants underwent Aβ imaging in research clinics in Perth and Melbourne and more than 72 months of follow-up (at 18-month intervals). The association of age with memory was fitted to a quadratic model. Age was treated as a continuous, time-dependent variable. Exposures: β-Amyloid imaging using positron emission tomography, genotyping for APOE ɛ4, and longitudinal neuropsychological assessments of episodic memory during the 72-month follow-up. Main Outcomes and Measures: Episodic memory composite score. Results: Of the 447 participants, 203 (45.4%) were men and 244 (54.6%) were women; mean (SD) age was 72.5 (6.6) years. Equal proportions of female participants were observed in each Aβ-ɛ4 group (24 of 51 Aβ-positive ε4 noncarriers [47.1%] ; 35 of 64 Aβ-negative ε4 carriers [54.7%]; 40 of 72 Aβ-positive ε4 carriers [55.6%]; and 145 of 260 Aβ-negative ε4 noncarriers [55.8%]). Adults with Aβ findings (mean [SD] age, 74.4 [6.8] years) were approximately 4 years older than those negative for Aβ (mean [SD] age, 69.8 [6.1] years). Memory decline diverged significantly from Aβ-negative ɛ4 noncarriers at an earlier age in Aβ-positive ɛ4 carriers (64.5 years) than in Aβ-positive ɛ4 noncarriers (76.5 years), such that by 85 years of age, Aβ-positive ε4 carriers performed approximately 1.5 SD units worse on the episodic memory composite than Aβ-negative ε4 noncarriers and approximately 0.8 SD units worse than Aβ-positive ε4 noncarriers. Memory performance of Aβ-negative ɛ4 carriers did not differ from that of the Aβ-negative ɛ4 noncarriers (estimate [SE], 0.001 [0.001]; t = 0.526; P = .77). Conclusions and Relevance: Prior work has shown that Aβ and ε4 combine to influence memory decline in nondemented older adults. Results of this study indicate that increasing age may further exacerbate these effects. The estimates provided may be used to determine the risk of memory decline associated with Aβ and ε4 at each age.
Importance: Older age, high levels of β-amyloid (Aβ), and the presence of the apolipoprotein E (APOE) ε4 allele are risk factors for Alzheimer disease (AD). However, the extent to which increasing age, Aβ, and ε4 are associated with memory decline remains unclear, and the age at which memory decline begins for Aβ-positive ε4 carriers and noncarriers has not been determined. Objective: To determine the association of age, Aβ level, and APOE ε4 with memory decline in a large group of cognitively healthy older adults. Design, Setting, and Participants: This longitudinal observational study included cognitively healthy older adults (age >60 years) enrolled in the Australian Imaging, Biomarkers and Lifestyle (AIBL) study from March 31, 2006, through March 31, 2017; of 1583 individuals enrolled, 1136 refused or were excluded owing to other criteria (eg, having mild cognitive impairment or AD). Participants underwent Aβ imaging in research clinics in Perth and Melbourne and more than 72 months of follow-up (at 18-month intervals). The association of age with memory was fitted to a quadratic model. Age was treated as a continuous, time-dependent variable. Exposures: β-Amyloid imaging using positron emission tomography, genotyping for APOE ɛ4, and longitudinal neuropsychological assessments of episodic memory during the 72-month follow-up. Main Outcomes and Measures: Episodic memory composite score. Results: Of the 447 participants, 203 (45.4%) were men and 244 (54.6%) were women; mean (SD) age was 72.5 (6.6) years. Equal proportions of female participants were observed in each Aβ-ɛ4 group (24 of 51 Aβ-positive ε4 noncarriers [47.1%] ; 35 of 64 Aβ-negative ε4 carriers [54.7%]; 40 of 72 Aβ-positive ε4 carriers [55.6%]; and 145 of 260 Aβ-negative ε4 noncarriers [55.8%]). Adults with Aβ findings (mean [SD] age, 74.4 [6.8] years) were approximately 4 years older than those negative for Aβ (mean [SD] age, 69.8 [6.1] years). Memory decline diverged significantly from Aβ-negative ɛ4 noncarriers at an earlier age in Aβ-positive ɛ4 carriers (64.5 years) than in Aβ-positive ɛ4 noncarriers (76.5 years), such that by 85 years of age, Aβ-positive ε4 carriers performed approximately 1.5 SD units worse on the episodic memory composite than Aβ-negative ε4 noncarriers and approximately 0.8 SD units worse than Aβ-positive ε4 noncarriers. Memory performance of Aβ-negative ɛ4 carriers did not differ from that of the Aβ-negative ɛ4 noncarriers (estimate [SE], 0.001 [0.001]; t = 0.526; P = .77). Conclusions and Relevance: Prior work has shown that Aβ and ε4 combine to influence memory decline in nondemented older adults. Results of this study indicate that increasing age may further exacerbate these effects. The estimates provided may be used to determine the risk of memory decline associated with Aβ and ε4 at each age.
Authors: Rik Vandenberghe; Koen Van Laere; Adrian Ivanoiu; Eric Salmon; Christine Bastin; Eric Triau; Steen Hasselbalch; Ian Law; Allan Andersen; Alex Korner; Lennart Minthon; Gaëtan Garraux; Natalie Nelissen; Guy Bormans; Chris Buckley; Rikard Owenius; Lennart Thurfjell; Gill Farrar; David J Brooks Journal: Ann Neurol Date: 2010-09 Impact factor: 10.422
Authors: R J Caselli; A C Dueck; D E C Locke; C R Hoffman-Snyder; B K Woodruff; S Z Rapcsak; E M Reiman Journal: Neurology Date: 2011-04-19 Impact factor: 9.910
Authors: Rik Ossenkoppele; Willemijn J Jansen; Gil D Rabinovici; Dirk L Knol; Wiesje M van der Flier; Bart N M van Berckel; Philip Scheltens; Pieter Jelle Visser; Sander C J Verfaillie; Marissa D Zwan; Sofie M Adriaanse; Adriaan A Lammertsma; Frederik Barkhof; William J Jagust; Bruce L Miller; Howard J Rosen; Susan M Landau; Victor L Villemagne; Christopher C Rowe; Dong Y Lee; Duk L Na; Sang W Seo; Marie Sarazin; Catherine M Roe; Osama Sabri; Henryk Barthel; Norman Koglin; John Hodges; Cristian E Leyton; Rik Vandenberghe; Koen van Laere; Alexander Drzezga; Stefan Forster; Timo Grimmer; Pascual Sánchez-Juan; Jose M Carril; Vincent Mok; Vincent Camus; William E Klunk; Ann D Cohen; Philipp T Meyer; Sabine Hellwig; Andrew Newberg; Kristian S Frederiksen; Adam S Fleisher; Mark A Mintun; David A Wolk; Agneta Nordberg; Juha O Rinne; Gaël Chételat; Alberto Lleo; Rafael Blesa; Juan Fortea; Karine Madsen; Karen M Rodrigue; David J Brooks Journal: JAMA Date: 2015-05-19 Impact factor: 56.272
Authors: Yen Ying Lim; Robert H Pietrzak; Pierrick Bourgeat; David Ames; Kathryn A Ellis; Alan Rembach; Karra Harrington; Olivier Salvado; Ralph N Martins; Peter J Snyder; Colin L Masters; Christopher C Rowe; Victor L Villemagne; Paul Maruff Journal: Arch Clin Neuropsychol Date: 2014-12-02 Impact factor: 2.813
Authors: Clifford R Jack; Heather J Wiste; Stephen D Weigand; David S Knopman; Prashanthi Vemuri; Michelle M Mielke; Val Lowe; Matthew L Senjem; Jeffrey L Gunter; Mary M Machulda; Brian E Gregg; V Shane Pankratz; Walter A Rocca; Ronald C Petersen Journal: JAMA Neurol Date: 2015-05 Impact factor: 18.302
Authors: Richard J Caselli; Amylou C Dueck; David Osborne; Marwan N Sabbagh; Donald J Connor; Geoffrey L Ahern; Leslie C Baxter; Steven Z Rapcsak; Jiong Shi; Bryan K Woodruff; Dona E C Locke; Charlene Hoffman Snyder; Gene E Alexander; Rosa Rademakers; Eric M Reiman Journal: N Engl J Med Date: 2009-07-16 Impact factor: 91.245
Authors: Vincent Doré; Victor L Villemagne; Pierrick Bourgeat; Jurgen Fripp; Oscar Acosta; Gael Chetélat; Luping Zhou; Ralph Martins; Kathryn A Ellis; Colin L Masters; David Ames; Oliver Salvado; Christopher C Rowe Journal: JAMA Neurol Date: 2013-07 Impact factor: 18.302
Authors: Victor L Villemagne; Samantha Burnham; Pierrick Bourgeat; Belinda Brown; Kathryn A Ellis; Olivier Salvado; Cassandra Szoeke; S Lance Macaulay; Ralph Martins; Paul Maruff; David Ames; Christopher C Rowe; Colin L Masters Journal: Lancet Neurol Date: 2013-03-08 Impact factor: 44.182
Authors: Lisa Vermunt; Sietske A M Sikkes; Ardo van den Hout; Ron Handels; Isabelle Bos; Wiesje M van der Flier; Silke Kern; Pierre-Jean Ousset; Paul Maruff; Ingmar Skoog; Frans R J Verhey; Yvonne Freund-Levi; Magda Tsolaki; Åsa K Wallin; Marcel Olde Rikkert; Hilkka Soininen; Luisa Spiru; Henrik Zetterberg; Kaj Blennow; Philip Scheltens; Graciela Muniz-Terrera; Pieter Jelle Visser Journal: Alzheimers Dement Date: 2019-06-01 Impact factor: 21.566
Authors: Athena C-J Wang; Christina Coughlan; Noah R Johnson; Stefan Sillau; Esteban Lucero; Lisa Viltz; Neil Markham; Cody Allen; A Ranjitha Dhanasekaran; Heidi J Chial; Huntington Potter Journal: Alzheimers Res Ther Date: 2022-06-29 Impact factor: 8.823
Authors: Emily Rosenich; Lisa Bransby; Nawaf Yassi; Jurgen Fripp; Simon M Laws; Ralph N Martins; Christopher Fowler; Stephanie R Rainey-Smith; Christopher C Rowe; Colin L Masters; Paul Maruff; Yen Ying Lim Journal: Neurology Date: 2022-02-15 Impact factor: 11.800
Authors: Michael E Belloy; Valerio Napolioni; Summer S Han; Yann Le Guen; Michael D Greicius Journal: JAMA Neurol Date: 2020-07-01 Impact factor: 18.302
Authors: Christopher Fowler; Stephanie R Rainey-Smith; Sabine Bird; Julia Bomke; Pierrick Bourgeat; Belinda M Brown; Samantha C Burnham; Ashley I Bush; Carolyn Chadunow; Steven Collins; James Doecke; Vincent Doré; Kathryn A Ellis; Lis Evered; Amir Fazlollahi; Jurgen Fripp; Samantha L Gardener; Simon Gibson; Robert Grenfell; Elise Harrison; Richard Head; Liang Jin; Adrian Kamer; Fiona Lamb; Nicola T Lautenschlager; Simon M Laws; Qiao-Xin Li; Lucy Lim; Yen Ying Lim; Andrea Louey; S Lance Macaulay; Lucy Mackintosh; Ralph N Martins; Paul Maruff; Colin L Masters; Simon McBride; Lidija Milicic; Madeline Peretti; Kelly Pertile; Tenielle Porter; Morgan Radler; Alan Rembach; Joanne Robertson; Mark Rodrigues; Christopher C Rowe; Rebecca Rumble; Olivier Salvado; Greg Savage; Brendan Silbert; Magdalene Soh; Hamid R Sohrabi; Kevin Taddei; Tania Taddei; Christine Thai; Brett Trounson; Regan Tyrrell; Michael Vacher; Shiji Varghese; Victor L Villemagne; Michael Weinborn; Michael Woodward; Ying Xia; David Ames Journal: J Alzheimers Dis Rep Date: 2021-06-03